- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016
OXFORD, United Kingdom, Sept. 05, 2016 (GLOBE NEWSWIRE) — Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the second quarter and half year ended 31 July 2016 on Thursday, 8 September 2016. Summit will host …
OXFORD, United Kingdom, Sept. 05, 2016 (GLOBE NEWSWIRE) — Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the second quarter and half year ended 31 July 2016 on Thursday, 8 September 2016.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the half year results press release and a replay of the call will also be available through the Company’s website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit Therapeutics | ||
Glyn Edwards / Richard Pye (UK office) | Tel: +44 (0)1235 443 951 | |
Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
Cairn Financial Advisers LLP | ||
(Nominated Adviser) | ||
Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 | |
N+1 Singer | ||
(Broker) | ||
Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 | |
MacDougall Biomedical Communications | ||
(US media contact) | Tel: +1 781 235 3060 | |
Chris Erdman / Karen Sharma | cerdman@macbiocom.com / | |
ksharma@macbiocom.com | ||
Consilium Strategic Communications | ||
(Financial public relations, UK) | Tel: +44 (0)20 3709 5700 | |
Mary-Jane Elliott / Sue Stuart / | summit@consilium-comms.com | |
Jessica Hodgson / Lindsey Neville |
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.